Lipid mediator class switching during acute inflammation: signals in resolution
The DOI matches its Crossref record; 41 of the 42 references it cites were found in a registry or an index.
Abstract
Leukotrienes (LTs) and prostaglandins (PGs) amplify acute inflammation, whereas lipoxins (LXs) have unique anti-inflammatory actions. Temporal analyses of these eicosanoids in clinical and experimental exudates showed early coordinate appearance of LT and PG with polymorphonuclear neutrophil (PMN) recruitment. This was followed by LX biosynthesis, which was concurrent with spontaneous resolution. Human peripheral blood PMNs exposed to PGE2 (as in exudates) switched eicosanoid biosynthesis from predominantly LTB4 and 5-lipoxygenase (5-LO)-initiated pathways to LXA4, a 15-LO product that "stopped" PMN infiltration. These results indicate that first-phase eicosanoids promote a shift to anti-inflammatory lipids: functionally distinct lipid-mediator profiles switch during acute exudate formation to "reprogram" the exudate PMNs to promote resolution.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Prostaglandin E2 (PGE2) and D2 rapidly initiate the resolution process by inducing the expression of lipid mediators with both anti-inflammatory and pre-resolution functions, e.g., lipoxins [96, 97], resolvins and protectins [98–100], a process known as lipid-mediator class switch [97].”
From Transition from inflammation to proliferation: a critical step during wound healing (2016) · cites this paper as [97]
Citations
Cites
Inflammation. Basic principles and clinical correlates
(1989) · Biomedicine & Pharmacotherapy · doi:10.1016/0753-3322(89)90156-x · Cited by 2,393
Inducible cyclooxygenase may have anti-inflammatory properties
Gilroy, D. W., Colville-Nash, P. R., Willis, D., Chivers, J., Paul-Clark, M. J., & Willoughby, D. A. (1999) · Nature Medicine · doi:10.1038/9550 · Cited by 1,242
Godson, C., Mitchell, S., Harvey, K., Petasis, N. A., Hogg, N., & Brady, H. R. (2000) · The Journal of Immunology · doi:10.4049/jimmunol.164.4.1663 · Cited by 638
Inflammation: Basic Principles and Clinical Correlates
Ehrlich, G. E. (2000) · JAMA: The Journal of the American Medical Association · doi:10.1001/jama.283.1.123 · Cited by 622
Shinmura, K., Tang, X.-L., Wang, Y., Xuan, Y.-T., Liu, S.-Q., Takano, H., Bhatnagar, A., & Bolli, R. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.97.18.10197 · Cited by 381
Swan, S. K., Rudy, D. W., Lasseter, K. C., Ryan, C. F., Buechel, K. L., Lambrecht, L. J., Pinto, M. B., Dilzer, S. C., Obrda, O., Sundblad, K. J., et al. (2000) · Annals of Internal Medicine · doi:10.7326/0003-4819-133-1-200007040-00002 · Cited by 339
Design of Lipoxin A4 Stable Analogs That Block Transmigration and Adhesion of Human Neutrophils
Serhan, C. N., Maddox, J. F., Petasis, N. A., Akritopoulou-Zanze, I., Papayianni, A., Brady, H. R., Colgan, S. P., & Madara, J. L. (1995) · Biochemistry · doi:10.1021/bi00044a041 · Cited by 327
Self-citationActivation of the NF-κB Pathway by Inflammatory Stimuli in Human Neutrophils
McDonald, P. P., Bald, A., & Cassatella, M. A. (1997) · Blood · doi:10.1182/blood.v89.9.3421 · Cited by 324
Prostaglandins, Aspirin-like Drugs and the Oedema of Inflammation
MONCADA, S., FERREIRA, S. H., & VANE, J. R. (1973) · Nature · doi:10.1038/246217a0 · Cited by 312 · cited 1×
“Although PGE 2 induces reactions that mediate several of the cardinal features of inflammation (for example, edem”
BackgroundTessier, P. A., Naccache, P. H., Clark-Lewis, I., Gladue, R. P., Neote, K. S., & McColl, S. R. (1997) · The Journal of Immunology · doi:10.4049/jimmunol.159.7.3595 · Cited by 233
Research works printed but not linked: 2
- Light, R. W. Pleural Diseases (Lea & Febiger, Philadelphia, 1990).
- Clish, C. B. et al. Local and systemic delivery of a stable aspirin-triggered lipoxin prevents neutrophil recruitment in vivo. Proc. Natl Acad Sci USA 96, 8247–8252 (1999). · DOI · Paper page
Cited by
Items 301–400 of 1,000
Anesthetics Impact the Resolution of Inflammation
Chiang, N., Schwab, J. M., Fredman, G., Kasuga, K., Gelman, S., & Serhan, C. N. (2008) · PLoS ONE · doi:10.1371/journal.pone.0001879 · Cited by 109
“PGE2, a signal that can activate the full LXA4-biosynthetic capacity in vivo [17], was present in the peritoneum prior to peritonitis and elevated during the acute inflammatory response.”
BackgroundSelf-citationResolution of inflammation: state of the art, definitions and terms
Serhan, C. N., Brain, S. D., Buckley, C. D., Gilroy, D. W., Haslett, C., O'Neill, L. A. J., Perretti, M., Rossi, A. G., & Wallace, J. L. (2006) · The FASEB Journal · doi:10.1096/fj.06-7227com · Cited by 142
Self-citationCodagnone, M., Cianci, E., Lamolinara, A., Mari, V. C., Nespoli, A., Isopi, E., Mattoscio, D., Arita, M., Bragonzi, A., Iezzi, M., et al. (2017) · Mucosal Immunology · doi:10.1038/mi.2017.36 · Cited by 111
Resolvins and protectins: Natural pharmacophores for resolution biology
Levy, B. D. (2010) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2010.02.003 · Cited by 124
Self-citationHavixbeck, J. J., Rieger, A. M., Wong, M. E., Hodgkinson, J. W., & Barreda, D. R. (2015) · Journal of Leukocyte Biology · doi:10.1189/jlb.3hi0215-064r · Cited by 129
“ELISAs were performed as previously described [30], with minor modifica-”
BackgroundMethodLipid mediators in immune regulation and resolution
Gilroy, D. W., & Bishop‐Bailey, D. (2019) · British Journal of Pharmacology · doi:10.1111/bph.14587 · Cited by 118
Kutzner, L., Rund, K. M., Ostermann, A. I., Hartung, N. M., Galano, J., Balas, L., Durand, T., Balzer, M. S., David, S., & Schebb, N. H. (2019) · Frontiers in Pharmacology · doi:10.3389/fphar.2019.00169 · Cited by 115
“Resolution of inflammation is introduced by a lipid mediator class switching characterized by a shift from the predominantly pro-inflammatory mediators such as leukotrienes that amplify acute inflammation to the mostly anti-inflammatory pro-resolving lipoxins (LX) (Levy et al., 2001).”
BackgroundResolvins: Emerging Players in Autoimmune and Inflammatory Diseases
Abdolmaleki, F., Kovanen, P. T., Mardani, R., Hayat, S. M. G., Bo, S., & Sahebkar, A. (2019) · Clinical Reviews in Allergy & Immunology · doi:10.1007/s12016-019-08754-9 · Cited by 117
“Changing the phase to resolution of inflammation, some eicosanoids such as PGE2 and PGD2, provokes the biosynthesis of pro-resolving lipid mediators such as lipoxin A4 (LXA4), deriving from arachidonic acid, that acts as an endogenous “stop” signal to control the resolution phase within hours up to days [18, 19].”
BackgroundSpecialized pro-resolving mediators as modulators of immune responses
Julliard, W. A., Myo, Y. P. A., Perelas, A., Jackson, P., Thatcher, T. H., & Sime, P. J. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101605 · Cited by 122
Odaka, C., Mizuochi, T., Yang, J., & Ding, A. (2003) · The Journal of Immunology · doi:10.4049/jimmunol.171.3.1507 · Cited by 104
“Two recent studies indicated that noninflammatory clearance of apoptotic cells could be regulated by anti-inflammatory lipid mediators (48, 49).”
BackgroundSerhan, C. N., & Chiang, N. (2004) · Rheumatic Disease Clinics of North America · doi:10.1016/s0889-857x(03)00117-0 · Cited by 120
“This was followed by LX biosynthesis, which was concurrent with spontaneous resolution [24].”
BackgroundSelf-citationNovel Chemical Mediators in the Resolution of Inflammation: Resolvins and Protectins
Serhan, C. N. (2006) · Anesthesiology Clinics of North America · doi:10.1016/j.atc.2006.01.003 · Cited by 113
“Once a neutrophil jumps into an exudate, it can, by interacting with cells in the immediate environment (ie, other leukocytes, blood-borne cell types, platelets, endothelia, mucosal epithelia [42] or interstitial cells, and fibroblasts), undergo transcellular biosynthesis and switch its lipid mediator profile from, fo…”
BackgroundInfluentialSelf-citationSpecialized Pro-Resolving Mediators as Resolution Pharmacology for the Control of Pain and Itch
Ji, R. (2022) · The Annual Review of Pharmacology and Toxicology · doi:10.1146/annurev-pharmtox-051921-084047 · Cited by 114
Prüss, H., Rosche, B., Sullivan, A. B., Brommer, B., Wengert, O., Gronert, K., & Schwab, J. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0055859 · Cited by 103
“Furthermore, since endogenous LXA4 synthesis is limited despite sufficient substrate (15-HETE) which is in line with a defective ‘‘lipid mediator class switch’’ [18], it might be worthwhile analyzing whether aspirin-triggered epimeric LXA4 levels can also be boosted in the CSF of MS patients, as has been demonstrated…”
BackgroundSelf-citationEicosanoids in skin inflammation
Nicolaou, A. (2013) · Prostaglandins, Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2012.03.009 · Cited by 101
Crucial Role of Macrophage Selenoproteins in Experimental Colitis
Kaushal, N., Kudva, A. K., Patterson, A. D., Chiaro, C. R., Kennett, M. J., Desai, D. H., Amin, S., Carlson, B. A., Cantorna, M. T., & Prabhu, K. S. (2014) · The Journal of Immunology · doi:10.4049/jimmunol.1400347 · Cited by 106
“Thus, inhibition of PGE2 could be a double-edged sword because of its proangiogenic role in the maintenance of mucosal integrity in experimental colitis (12) and its link to the activation of resolution by stimulating the eicosanoid class switching to anti-inflammatory and proresolving mediators in human leukocytes (1…”
BackgroundRole of Neutrophil Apoptosis in the Resolution of Inflammation
Kebir, D. E., & Filep, J. G. (2010) · The Scientific World JOURNAL · doi:10.1100/tsw.2010.169 · Cited by 115
“Accumulation of PGE2 at inflammatory sites induces a lipid mediator class switching from a predominantly 5-lipoxygenase activity to a 15lipoxygenase activity generating LXA4 parallel with the resolution of inflammation[65].”
BackgroundKulkarni, O. P., Lichtnekert, J., Anders, H., & Mulay, S. R. (2016) · Mediators of Inflammation · doi:10.1155/2016/2856213 · Cited by 128
“This is often followed by the class switching of lipid mediators, in which arachidonic acid metabolism switches from the production of leukotrienes to anti-inflammatory lipoxins, thus sending the “stop” signal to neutrophils recruitment and begins the end of the acute inflammatory response [17].”
BackgroundNon-steroidal anti-inflammatory drugs, pharmacology, and COVID-19 infection
Micallef, J., Soeiro, T., & Jonville‐Béra, A. ‐. (2020) · Therapies · doi:10.1016/j.therap.2020.05.003 · Cited by 110
“Other studies suggest that NSAIDs could also affect the severity of bacterial infections through several mechanisms, such as an increase in the production of inflammatory cytokines (TNF-α, interleukin-1, and interleukin-6) [36] [37] [38] 34, 35, 30] .”
Lipidomic profiling of bioactive lipids by mass spectrometry during microbial infections
Tam, V. C. (2013) · Seminars in Immunology · doi:10.1016/j.smim.2013.08.006 · Cited by 110
“PGE2 along with PGD2 also upregulates 15-LOX, giving rise to lipid mediator class switching and promoting the biosynthesis of pro-resolving mediators [24].”
Cordaro, M., Cuzzocrea, S., & Crupi, R. (2020) · Antioxidants · doi:10.3390/antiox9030216 · Cited by 98
Gao, Y., Min, K., Zhang, Y.-B., Su, J. C., Greenwood, M., & Gronert, K. (2015) · The Journal of Immunology · doi:10.4049/jimmunol.1500610 · Cited by 109
“Expression of 5-LOX was 9–21-fold higher in inflammatory PMNs compared with tissue PMNs, whereas expression of 15-LOX, a marker of leukocyte housekeeping function (16), was 25–656-fold higher in tissue PMNs than in inflammatory PMNs.”
BackgroundSelf-citationSerhan, C. N. (2008) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2008.09.012 · Cited by 108
Self-citationSuccess of prostaglandin E 2 in structure–function is a challenge for structure-based therapeutics
Serhan, C. N., & Levy, B. (2003) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1733589100 · Cited by 98
Self-citationVong, L., Ferraz, J. G. P., Dufton, N., Panaccione, R., Beck, P. L., Sherman, P. M., Perretti, M., & Wallace, J. L. (2012) · PLoS ONE · doi:10.1371/journal.pone.0039244 · Cited by 98
“Although recruited to extinguish a pro-inflammatory stimulus, there is emerging evidence that infiltrating leukocytes also release anti-inflammatory mediators to trigger resolution [4,5].”
Lipoxins: Potential anti-inflammatory, proresolution, and antifibrotic mediators in renal disease
Kieran, N. E., MADERNA, P., & Godson, C. (2004) · Kidney International · doi:10.1111/j.1523-1755.2004.00487.x · Cited by 100
Murata, T., Aritake, K., Tsubosaka, Y., Maruyama, T., Nakagawa, T., Hori, M., Hirai, H., Nakamura, M., Narumiya, S., Urade, Y., et al. (2013) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1218091110 · Cited by 107
“Lipoxins are antiinflammatory lipid mediators that potently inhibit neutrophil infiltration (19).”
BackgroundMicroscale arrays for the profiling of start and stop signals coordinating human-neutrophil swarming
Reátegui, E., Jalali, F., Khankhel, A. H., Wong, E. A., Cho, H., Lee, J., Serhan, C. N., Dalli, J., Elliott, H. L., & Irimia, D. (2017) · Nature Biomedical Engineering · doi:10.1038/s41551-017-0094 · Cited by 103
“± 1.0 pg/mL), suggesting a complex interplay of signals and the presence of an equilibrium point or “eicosanoid switch” 18 .”
BackgroundInfluentialSelf-citationThe mechanism of retinol-induced irritation and its application to anti-irritant development
Kim, B., Lee, Y.-S., & Kang, K.-S. (2003) · Toxicology Letters · doi:10.1016/j.toxlet.2003.09.001 · Cited by 101
“Inflammatory events involve numerous soluble chemical mediators such as histamine, kinin, arachidonic acid and metabolites, nitric oxide, serotonin, oxygen derived free radicals and cytokines (Levy et al., 2001).”
BackgroundLipoxin biosynthesis in inflammatory bowel disease
Mangino, M. J., Brounts, L. R., Harms, B., & Heise, C. P. (2005) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2005.10.004 · Cited by 107
Exogenous Pathogen and Plant 15-Lipoxygenase Initiate Endogenous Lipoxin A4 Biosynthesis
Bannenberg, G. L., Aliberti, J., Hong, S., Sher, A., & Serhan, C. N. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20031325 · Cited by 98
“, when PGE2 present in the inflammatory exudate activates the rapid translation of 15-lipoxygenase message that, together with already present 5-lipoxygenase, establishes a complete lipoxin biosynthetic circuit within the human neutrophil (17).”
BackgroundSelf-citationSerhan, C. N., Libreros, S., & Nshimiyimana, R. (2022) · Seminars in Immunology · doi:10.1016/j.smim.2022.101597 · Cited by 111
“The prostaglandins PGE2 and PGD2 activate the lipid mediator class switch [13], triggering the increase in 15-lipoxygenase [211] that leads to production of lipoxins starting the decrease in neutrophil numbers in the”
Self-citationChen, S. (2011) · Current Drug Targets · doi:10.2174/138945011794815347 · Cited by 98
Kalsotra, A., Zhao, J., Anakk, S., Dash, P. K., & Strobel, H. W. (2006) · Journal of Cerebral Blood Flow & Metabolism · doi:10.1038/sj.jcbfm.9600396 · Cited by 100
“Levy et al (2001) have shown a time-based switching from proinflammatory to anti-inflammatory eicosanoids after tumor necrosis factor-a mediated inflammation in the murine dorsal air pouch.”
BackgroundNorling, L. V., & Serhan, C. N. (2010) · Journal of Internal Medicine · doi:10.1111/j.1365-2796.2010.02235.x · Cited by 115
Self-citationComplement and human T cell metabolism: Location, location, location
West, E. E., Kunz, N., & Kemper, C. (2020) · Immunological Reviews · doi:10.1111/imr.12852 · Cited by 99
Jordan, P. M., Gerstmeier, J., Pace, S., Bilancia, R., Rao, Z., Börner, F., Miek, L., Gutiérrez‐Gutiérrez, Ó., Arakandy, V., Rossi, A., et al. (2020) · Cell Reports · doi:10.1016/j.celrep.2020.108247 · Cited by 100
“Such a temporal switch from pro-inflammatory to pro-resolving LMs is decisive for inflammation termination (Levy et al., 2001; Serhan and Levy, 2018) and may be promoted by Hla.”
BackgroundSelf-citationNeutrophil diversity in inflammation and cancer
Carnevale, S., Ceglie, I. D., Grieco, G., Rigatelli, A., Bonavita, E., & Jaillon, S. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1180810 · Cited by 104
Dakin, S. G., Werling, D., Hibbert, A. P., Abayasekara, D. R. E., Young, N. J., Smith, R. K. W., & Dudhia, J. (2012) · PLoS ONE · doi:10.1371/journal.pone.0032333 · Cited by 107
“promote resolution of inflammation and the return of tissues to their normal homeostatic state [39,44,51,52,53].”
BackgroundArachidonic acid and lipoxin A4 as possible endogenous anti-diabetic molecules
Das, U. N. (2013) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2012.11.009 · Cited by 99
“AA, EPA and DHA also give rise to anti-inflammatory lipoxins; resolvins, protectins and maresins [15–26] (see Figs.”
BackgroundHellmann, J., Zhang, M. J., Tang, Y., Rane, M., Bhatnagar, A., & Spite, M. (2013) · The Journal of Immunology · doi:10.4049/jimmunol.1203369 · Cited by 93
“(53) show that lipid mediator class switching”
Das, U. N. (2007) · Prostaglandins Leukotrienes and Essential Fatty Acids · doi:10.1016/j.plefa.2007.03.001 · Cited by 103
“5,12,18R-triHEPE competed with LTB4 for its receptors and inhibited PMN infiltration, and thus, 5,12,18R-triHEPE suppresses LT-mediated responses when present at the sites of inflammation [1,29–32].”
BackgroundALOX15 as a suppressor of inflammation and cancer: Lost in the link
Tian, R., Zuo, X., Jaoude, J. C., Mao, F., Colby, J. K., & Shureiqi, I. (2017) · Prostaglandins & Other Lipid Mediators · doi:10.1016/j.prostaglandins.2017.01.002 · Cited by 101
A novel rat lipoxin A4 receptor that is conserved in structure and function
Chiang, N., Takano, T., Arita, M., Watanabe, S., & Serhan, C. N. (2003) · British Journal of Pharmacology · doi:10.1038/sj.bjp.0705220 · Cited by 91
“We and others have demonstrated that LXA4 and ATL inhibit release of select ‘proinflammatory cytokines’ (Hachicha et al., 1999) and promote resolution (Godson et al., 2000; Levy et al., 2001).”
BackgroundSelf-citationThe skin pathergy test: innately useful?
Varol, A., Seifert, O., & Anderson, C. D. (2009) · Archives of Dermatological Research · doi:10.1007/s00403-009-1008-9 · Cited by 95
Reduced 15-lipoxygenase 2 and lipoxin A4/leukotriene B4ratio in children with cystic fibrosis
Ringholz, F., Buchanan, P., Clarke, D., Millar, R. G., McDermott, M., Linnane, B. M., Harvey, B. J., McNally, P., & Urbach, V. (2014) · European Respiratory Journal · doi:10.1183/09031936.00106013 · Cited by 90
Resolution-associated molecular patterns (RAMP): RAMParts defending immunological homeostasis?
Shields, A. M., Panayi, G. S., & Corrigall, V. M. (2011) · Clinical and Experimental Immunology · doi:10.1111/j.1365-2249.2011.04433.x · Cited by 90
Impaired Resolution of Inflammation in Alzheimer’s Disease: A Review
Whittington, R. A., Planel, E., & Terrando, N. (2017) · Frontiers in Immunology · doi:10.3389/fimmu.2017.01464 · Cited by 88
Watrous, J. D., Niiranen, T. J., Lagerborg, K. A., Henglin, M., Xu, Y.-J., Rong, J., Sharma, S., Vasan, R. S., Larson, M. G., Armando, A., et al. (2019) · Cell Chemical Biology · doi:10.1016/j.chembiol.2018.11.015 · Cited by 90
12/15-Lipoxygenase Regulates the Inflammatory Response to Bacterial Products In Vivo
Dioszeghy, V., Rosas, M., Maskrey, B. H., Colmont, C., Topley, N., Chaitidis, P., Kühn, H., Jones, S. A., Taylor, P. R., & O'Donnell, V. B. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.181.9.6514 · Cited by 89
Neutrophil apoptosis: A target for enhancing the resolution of inflammation
Filep, J. G., & Kebir, D. E. (2009) · Journal of Cellular Biochemistry · doi:10.1002/jcb.22351 · Cited by 105
“…synthesis from a predominantly 5-lipoxygenase activity to a 15-lipoxygenase activity generating LXA4 parallel with the resolution of inflammation [Levy et al., 2001] led to the suggestion that initiation of an inflammatory response also signals to activate subsequent pro-resolution mechanisms…”
BackgroundBiteman, B., Hassan, I. R., Walker, E., Leedom, A. J., Dunn, M., Seta, F., Laniado-Schwartzman, M., & Gronert, K. (2007) · The FASEB Journal · doi:10.1096/fj.06-7918com · Cited by 90
“matory (19, 22, 24) and neuroprotective (16, 29).”
Self-citationCho, H. K., Cheong, K. J., Kim, H. Y., & Cheong, J. (2011) · Biochemical Journal · doi:10.1042/bj20102071 · Cited by 95
Lipid mediators in immune dysfunction after severe inflammation
Fullerton, J. N., O’Brien, A. J., & Gilroy, D. W. (2014) · Trends in Immunology · doi:10.1016/j.it.2013.10.008 · Cited by 89
Carr, A. J., Murphy, R., Dakin, S. G., Rombach, I., Wheway, K., Watkins, B., & Franklin, S. L. (2015) · The American Journal of Sports Medicine · doi:10.1177/0363546515608485 · Cited by 89
“14) Length of symptoms, median (IQR) 24 (18-32) 19 (12-36) Baseline OSS, median (IQR) 26.”
Proresolving Lipid Mediators: Endogenous Modulators of Oxidative Stress
Leuti, A., Maccarrone, M., & Chiurchiù, V. (2019) · Oxidative Medicine and Cellular Longevity · doi:10.1155/2019/8107265 · Cited by 88
“Catabasis is eventually initiated as immune cells undergo a lipid mediator class switch [5], during which two main events occur: (i) AA metabolism is channelled into the production of lipoxins (LXs) that in turn are thought to initiate resolution and (ii) other PUFAs such as EPA, DHA, and DPA start being used as biosy…”
BackgroundResolving inflammation by TAM receptor activation
Vago, J. P., Amaral, F. A., & van de Loo, F. A. J. (2021) · Pharmacology & Therapeutics · doi:10.1016/j.pharmthera.2021.107893 · Cited by 95
Dietary n-3 long chain PUFA supplementation promotes a pro-resolving oxylipin profile in the brain
Rey, C., Delpech, J.-C., Madore, C., Nadjar, A., Greenhalgh, A. D., Amadieu, C., Aubert, A., Pallet, V., Vaysse, C., Layé, S., et al. (2018) · Brain Behavior and Immunity · doi:10.1016/j.bbi.2018.07.025 · Cited by 99
“…that the mechanisms underlying the anti-inflammatory effect of DHA and EPA in the brain involve n-3 LC-PUFA derived bioactive mediators, called oxylipins, which promote the resolution of inflammation (Serhan et al., 2000, Levy et al., 2001, Hong et al., 2003, Serhan et al., 2015, Rey et al., 2016).”
BackgroundEndogenous lipid mediators in the resolution of airway inflammation
Haworth, O., & Levy, B. D. (2007) · European Respiratory Journal · doi:10.1183/09031936.00005807 · Cited by 88
Self-citationLipidCreator workbench to probe the lipidomic landscape
Peng, B., Kopczynski, D., Pratt, B. S., Ejsing, C. S., Burla, B., Hermansson, M., Benke, P. I., Tan, S. H., Chan, M. Y., Torta, F. T., et al. (2020) · Nature Communications · doi:10.1038/s41467-020-15960-z · Cited by 90
Vong, L., Ferraz, J. G., Panaccione, R., Beck, P. L., & Wallace, J. L. (2010) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.1004982107 · Cited by 87
Specialized Proresolving Mediators in Innate and Adaptive Immune Responses in Airway Diseases
Krishnamoorthy, N., Abdulnour, R.-E. E., Walker, K. H., Engstrom, B. D., & Levy, B. D. (2018) · Physiological Reviews · doi:10.1152/physrev.00026.2017 · Cited by 89
Self-citationDietary arachidonic acid: harmful, harmless or helpful?
Calder, P. C. (2007) · British Journal Of Nutrition · doi:10.1017/s0007114507761779 · Cited by 101
Kowalski, M. L. (2003) · Journal of Allergy and Clinical Immunology · doi:10.1016/s0091-6749(03)00009-5 · Cited by 85
Koeberle, A., Laufer, S., & Werz, O. (2016) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01750 · Cited by 86
Fatty Acids and Immune Function: Relevance to Inflammatory Bowel Diseases
Calder, P. C. (2009) · International Reviews of Immunology · doi:10.3109/08830180903197480 · Cited by 84
“Increased generation of 5-series LTs has been demonstrated using macrophages from fish oil-fed mice [36], neutrophils from human subjects infused for several days with lipid emulsions containing fish oil [41–43], and neutrophils from humans supplemented with oral fish oil for several weeks [10–12].”
BackgroundPro-resolving lipid mediators in vascular disease
Conte, M. S., Desai, T. A., Wu, B., Schaller, M. S., & Werlin, E. C. (2018) · Journal of Clinical Investigation · doi:10.1172/jci97947 · Cited by 85
“Substrate utilization and biosynthesis pathways for omega-3 and omega-6 PUFA–derived mediators are complex and involve competition for the available enzymes (3, 9, 112–116).”
Lin, S., Mao, R., Qian, C., Bettenworth, D., Wang, J., Li, J., Bruining, D. H., Jairath, V., Feagan, B. G., Chen, M., et al. (2021) · Physiological Reviews · doi:10.1152/physrev.00005.2021 · Cited by 91
Ghesquiere, S. A. I., Gijbels, M. J. J., Anthonsen, M., van Gorp, P. J. J., van der Made, I., Johansen, B., Hofker, M. H., & de Winther, M. P. J. (2005) · Journal of Lipid Research · doi:10.1194/jlr.m400253-jlr200 · Cited by 82
Mechanisms of nonsteroidal anti-inflammatory drugs in cancer prevention
Umar, A., Steele, V. E., Menter, D. G., & Hawk, E. T. (2015) · Seminars in Oncology · doi:10.1053/j.seminoncol.2015.09.010 · Cited by 87
PKA regulatory IIα subunit is essential for PGD2-mediated resolution of inflammation
Kong, D., Shen, Y., Liu, G., Zuo, S., Ji, Y., Lu, A., Nakamura, M., Lazarus, M., Stratakis, C. A., Breyer, R. M., et al. (2016) · Journal of Experimental Medicine · doi:10.1084/jem.20160459 · Cited by 81
“Consistent with these observations, PGD2 induces 15-lypoxygenase expression and generation of pro-resolution LXA4 in polymorphonuclear neutrophils dependent on intracellular cAMP accumulation (Levy et al., 2001), perhaps through activation of a Gs-coupled DP1 receptor (Breyer et al.”
BackgroundInfluentialFattori, V., Zaninelli, T. H., Rasquel-Oliveira, F. S., Casagrande, R., & Verri, W. A., Jr. (2019) · Pharmacological Research · doi:10.1016/j.phrs.2019.104549 · Cited by 86
Barker, G., Leeuwenburgh, C., Brusko, T. M., Moldawer, L. L., Reddy, S. T., & Guirgis, F. W. (2021) · Journal of Clinical Medicine · doi:10.3390/jcm10081693 · Cited by 89
“As these mediators accumulate, prostaglandin E2 (PGE2) promotes a shift of eicosanoid biosynthesis towards lipoxin A4 (LXA4) generation, which opposes polymorphonuclear neutrophil (PMN) infiltration as well as functional responses [37].”
BackgroundResolvin D2 restores neutrophil directionality and improves survival after burns
Kurihara, T., Jones, C. N., Yu, Y., Fischman, A. J., Watada, S., Tompkins, R. G., Fagan, S. P., & Irimia, D. (2013) · The FASEB Journal · doi:10.1096/fj.12-219519 · Cited by 89
“To probe whether restoring the impaired neutrophil activity could improve the outcome of septic complications after burn injury, we measured the direct effects of recently discovered resolvins D1 and D2 (RvD1 and RvD2) on neutrophil chemotaxis (21, 22).”
BackgroundWang, X., Hjorth, E., Vedin, I., Eriksdotter, M., Freund-Levi, Y., Wahlund, L.-O., Cederholm, T., Palmblad, J., & Schultzberg, M. (2015) · Journal of Lipid Research · doi:10.1194/jlr.p055418 · Cited by 80
Pouliot, M., Fiset, M.-E., Massé, M., Naccache, P. H., & Borgeat, P. (2002) · The Journal of Immunology · doi:10.4049/jimmunol.169.9.5279 · Cited by 80
Resolvin D1 Reduces Emphysema and Chronic Inflammation
Hsiao, H.-M., Thatcher, T. H., Colas, R. A., Serhan, C. N., Phipps, R. P., & Sime, P. J. (2015) · American Journal Of Pathology · doi:10.1016/j.ajpath.2015.08.008 · Cited by 82
“21,22 PGE2 also plays a proresolving role by activating lipid class switching.(42) Increased EOR likely inhibits resolution by degrading proresolving mediators and by dampening PGE2-driven lipid class switching.”
Self-citationYacoubian, S., & Serhan, C. N. (2007) · Nature Clinical Practice Rheumatology · doi:10.1038/ncprheum0616 · Cited by 87
Self-citationLukashev, D. E., Smith, P. T., Caldwell, C. C., Ohta, A., Apasov, S. G., & Sitkovsky, M. V. (2003) · Biochemical Pharmacology · doi:10.1016/s0006-2952(03)00158-8 · Cited by 89
Translation Control: A Multifaceted Regulator of Inflammatory Response
Mazumder, B., Li, X., & Barik, S. (2010) · The Journal of Immunology · doi:10.4049/jimmunol.0903778 · Cited by 80
“However, the infiltrating neutrophils also deliver arachidonate to tissue cells that express 15-lipoxygenase; this catalyzes the conversion of arachidonate to lipoxins, which inhibit neutrophil influx (3, 45) (Fig.”
BackgroundHu, J., Vacas, S., Feng, X., Lutrin, D., Uchida, Y., Lai, I. K., & Maze, M. (2017) · Anesthesiology · doi:10.1097/aln.0000000000002038 · Cited by 85
Lipids and the immune response: from molecular mechanisms to clinical applications
Yaqoob, P. (2003) · Current Opinion in Clinical Nutrition & Metabolic Care · doi:10.1097/00075197-200303000-00002 · Cited by 88
Stotts, C., Corrales‐Medina, V., & Rayner, K. J. (2023) · Circulation Research · doi:10.1161/circresaha.122.321636 · Cited by 100
Jiao, Y., Zhang, T., Liu, M., Zhou, L., Qi, M., Xie, X., Shi, X., Gu, X., & Ma, Z. (2023) · Journal of Biomedical Science · doi:10.1186/s12929-023-00957-9 · Cited by 92
“In addition, previous studies have demonstrated that prostaglandin E2 (PGE2) produced by local macrophages switches lipid mediator biosynthesis from predominantly proinflammatory leukotriene B4 [LTB4; 5-lipoxygenase (5-LO)-initiated pathway] to anti-inflammatory lipoxin A4 (LXA4), a 15-LO product in PMNs [13, 14].”
BackgroundMasoodi, M., Pearl, D. S., Eiden, M., Shute, J. K., Brown, J. F., Calder, P. C., & Trebble, T. M. (2013) · PLoS ONE · doi:10.1371/journal.pone.0076532 · Cited by 87
“For example, PGE2 is produced via COX-1 and COX-2 within the AA cascade and has pro-inflammatory (via cytokine induction pathways) and anti-inflammatory (via lipoxin induction) effects [33,34].”
BackgroundTalvani, A., Machado, F. S., Santana, G. C., Klein, A., Barcelos, L. S., Silva, J. S., & Teixeira, M. M. (2002) · Infection and Immunity · doi:10.1128/iai.70.8.4247-4253.2002 · Cited by 79
“cruitment in several models of inflammation (9, 14).”
BackgroundProstanoids and Resolution of Inflammation – Beyond the Lipid-Mediator Class Switch
Schmid, T., & Brüne, B. (2021) · Frontiers in Immunology · doi:10.3389/fimmu.2021.714042 · Cited by 89
Endo‐Umeda, K., Kim, E., Thomas, D. G., Liu, W., Dou, H., Yalçınkaya, M., Abramowicz, S., Xiao, T., Antonson, P., Gustafsson, J.-Α., et al. (2022) · Arteriosclerosis Thrombosis and Vascular Biology · doi:10.1161/atvbaha.122.317583 · Cited by 86
Shiraishi, Y., Asano, K., Niimi, K., Fukunaga, K., Wakaki, M., Kagyo, J., Takihara, T., Ueda, S., Nakajima, T., Oguma, T., et al. (2008) · The Journal of Immunology · doi:10.4049/jimmunol.180.1.541 · Cited by 83
“PGE2 or forskolin, which elevates intracellular cAMP levels, has been demonstrated to induce the expression of 15-lipoxygenase and promote the lipoxin formation, which is essential for the resolution of inflammation (50).”
BackgroundNSAIDs in patients with viral infections, including Covid-19: Victims or perpetrators?
Capuano, A., Scavone, C., Racagni, G., & Scaglione, F. (2020) · Pharmacological Research · doi:10.1016/j.phrs.2020.104849 · Cited by 77
“A literature review of both preclinical and clinical studies on this topic was carried out.”
Filep, J. G., & Ariel, A. (2020) · American Journal of Physiology-Cell Physiology · doi:10.1152/ajpcell.00181.2020 · Cited by 89
Tsai, C., Hsieh, S., Liu, C., Lu, C.-S., Wu, C.-H., Liao, H., Chen, M., Li, K., Shen, C., Kuo, Y., et al. (2021) · International Journal of Molecular Sciences · doi:10.3390/ijms22063119 · Cited by 96
Mancini, A. D., & Battista, J. A. D. (2011) · Inflammation Research · doi:10.1007/s00011-011-0385-7 · Cited by 82
“[19]”
BackgroundLipid Mediators as Agonists for the Resolution of Acute Lung Inflammation and Injury
Bonnans, C., & Levy, B. D. (2006) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2006-0269tr · Cited by 85
“COX-2–derived PGD2 and PGE2 can serve as pivotal signals for switching from LTB4 to LXA4 biosynthesis in acute exudative inflammation (14), and after ALI, COX-2 inhibition blocked the increased LXA4 production, resulting in an exacerbation of ALI with longer recovery times (13).”
BackgroundSelf-citationLi, Y., Karlin, A., Loike, J. D., & Silverstein, S. C. (2004) · The Journal of Experimental Medicine · doi:10.1084/jem.20040725 · Cited by 77
“They are formed at sites of inflammation after entry of the first wave of neutrophils, but before the rate of neutrophil entry declines (18).”
BackgroundTherapeutic Potential of Lipoxin A4 in Chronic Inflammation: Focus on Cardiometabolic Disease
Fu, T., Mohan, M., Brennan, E. P., Woodman, O. L., Godson, C., Kantharidis, P., Ritchie, R. H., & Qin, C. X. (2020) · ACS Pharmacology & Translational Science · doi:10.1021/acsptsci.9b00097 · Cited by 83
Innovative Hydrogel Design: Tailoring Immunomodulation for Optimal Chronic Wound Recovery
Lai, C., Chen, W., Yuan, Q., Xu, D., Lai, Y., & He, S. (2024) · Advanced Science · doi:10.1002/advs.202412360 · Cited by 94
Diverse Ways of Perturbing the Human Arachidonic Acid Metabolic Network To Control Inflammation
Meng, H., Liu, Y., & Lai, L. (2015) · Accounts of Chemical Research · doi:10.1021/acs.accounts.5b00226 · Cited by 80
The role of resolvin D1 in the regulation of inflammatory and catabolic mediators in osteoarthritis
Benabdoune, H., Rondon, E.-P., Shi, Q., Fernandes, J., Ranger, P., Fahmi, H., & Benderdour, M. (2016) · Inflammation Research · doi:10.1007/s00011-016-0946-x · Cited by 87
Jerschow, E., Edin, M. L., Chi, Y., Hurst, B., Abuzeid, W. M., Akbar, N. A., Gibber, M. J., Fried, M. P., Han, W., Pelletier, T., et al. (2018) · The Journal of Allergy and Clinical Immunology In Practice · doi:10.1016/j.jaip.2018.12.014 · Cited by 84
“Last aspirin dose before the second post-ESS challenge, weeks (IQR) 15 (8-19) 12 (9-26) .”
Background
Metadata
- Authors
- Levy, B. D., Clish, C. B., Schmidt, B., Gronert, K., & Serhan, C. N.
- Affiliations
- Brigham and Women's Hospital (US)
- Corresponding author
- Serhan, Charles N.
- Venue
- Nature Immunology
- Published
- 2001-07
- Volume
- 2
- Issue
- 7
- Pages
- 612-619
- ISSN
- 1529-2908 (ISSN-L)
- 1529-2916
- OpenAlex
- W1497700962
- Cited by
- 1,453
- References
- 42
- Citations by year
- 2026: 48 · 2025: 60 · 2024: 61 · 2023: 74 · 2022: 74 · 2021: 81 · 2020: 76 · 2019: 64 · 2018: 69 · 2017: 62 · 2016: 62 · 2015: 63 · 2014: 62 · 2013: 69 · 2012: 60
- FWCI
- 33.62
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Immunology (publishedVersion)
- PubMed (publishedVersion)
- Funders
- National Institutes of Health (5k08hl003788-04)
- National Heart, Lung, and Blood Institute (K08 HL 03788)
- National Institute of General Medical Sciences (GM 38765)
- National Institute of Allergy and Infectious Diseases (F32AI010389, F32-AI10389)
- National Institute of Diabetes and Digestive and Kidney Diseases (DK-50305, P01DK050305, K01DK060583)
- National Institute of Dental and Craniofacial Research (P01 DE 13499, P01DE013499)
- Topics
- Health Sciences › Nursing › Nutrition and Dietetics › Fatty Acid Research and Health
- Health Sciences › Medicine › Pharmacology (medical) › Inflammatory mediators and NSAID effects
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Biochemistry › Eicosanoids and Hypertension Pharmacology
- Keywords
- lipid mediators, acute inflammation, inflammation resolution, leukotrienes, prostaglandins, lipoxins, eicosanoid biosynthesis, neutrophil recruitment, lipoxin A4, leukotriene B4, 5-lipoxygenase, 15-lipoxygenase, prostaglandin E2, exudate, anti-inflammatory signaling
- MeSH terms
- Animals, Arachidonate 15-Lipoxygenase, Base Sequence, Humans, Hydroxyeicosatetraenoic Acids, Leukotriene B4, Lipids, Male, Mice, Inbred BALB C, Molecular Sequence Data, Neutrophils, Pleural Effusion, RNA, Messenger, Dinoprostone, Molecular Structure, Signal Transduction, DNA, Complementary, Lipoxins, Lipid Metabolism, Mice
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.